Dalfampridine in multiple sclerosis

Drugs of Today

Volumn 46, Issue 9, 2010, Pages 635-639

  Goodman, Andrew David ^a   Hyland, M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; ACETYLCHOLINE; GLATIRAMER; INTERFERON; NATALIZUMAB; NEUROTRANSMITTER; PLACEBO; POTASSIUM CHANNEL; VOLTAGE GATED CHANNEL FORMING PROTEIN;

ACUTE BRAIN DISEASE; ANXIETY; ASTHENIA; BACKACHE; BALANCE DISORDER; BLOOD BRAIN BARRIER; BODY MASS; CALCIUM TRANSPORT; CONFUSION; DEMOGRAPHY; DEMYELINATION; DISEASE COURSE; DISEASE DURATION; DIZZINESS; DRUG BINDING; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG TISSUE LEVEL; FALLING; FATIGUE; FOCAL EPILEPSY; HEADACHE; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; NAUSEA; NERVE FIBER MEMBRANE POTENTIAL; NEUROTRANSMITTER RELEASE; REVIEW; SEIZURE; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WALKING SPEED;

4-AMINOPYRIDINE; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE SCLEROSIS; POTASSIUM CHANNEL BLOCKERS;

EID: 79955904469     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.9.1499027     Document Type: Review

References (19)

1. Goodman, A.D., Brown, T.R., Krupp, L.B. et al. Sustained-release oral dalfampridine in multiple sclerosis: A randomised, double-blind, controlled trial. Lancet 2009, 373(9665): 732-8.
2. http://www.nationalmssociety.org/about-multiple-sclerosis.
3. Hayes, K.C. The use of 4-aminopyridine (dalfampridine) in demyelinating disorders. CNS Drug Rev 2004, 10(4): 295-316.
4. Judge, S.I., Bever, C.T. Jr. Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006, 111(1): 224-59. (Pubitemid 43765538)
5. Hayes, K.C., Katz, M.A., Devane, J.G., Hsieh, J.T., Wolfe, D.L., Potter, P.J., Blight, A.R. Pharmacokinetcis of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 2003, 43(4): 379-85. (Pubitemid 36368779)
6. Korenke, A., Rivey, M., Allington, D. Sustained-release dalfampridine for symptomatic treatment of multiple sclerosis. Ann Pharmacother 2008, 42(10): 1458-65.
7. Smith, W., Swan, S., Marbury, T., Henney, H. 3rd. Single-dose pharmacokinetics of sustained-release fampridine (fampridine-SR) in healthy volunteers and adults with renal impairment. J Clin Pharmacol 2010, 50(2): 151-9.
8. Bever, C.T. Jr., Young, D., Tierney, D. et al. The pharmacokinetics and tolerability of a slow-release formulation of 4-aminopyridine in multiple sclerosis patients. Neurology 1995, 45(Suppl. 4): A35-42.
9. Jones, R.E., Heron, J.R., Foster, D.H., Snelgar, R.S., Mason, R.J. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983, 60(3): 353-62. (Pubitemid 13051185)
10. Davis, F.A., Stefoski, D., Rush, J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990, 27(2): 186-92. (Pubitemid 20086640)
11. Stefoski, D., Davis, F.A., Faut, M., Schauf, C.L. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987, 21(1): 71-7.
12. Bever, C.T., Young, D., Anderson, P.A. et al. The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, crossover trial. Neurology 1994, 44(6): 1054-9. (Pubitemid 24188176)
13. Schwid, S.R., Petrie, M.D., McDermott, M.P., Tierney, D.S., Mason, D.H., Goodman, A.D. Quantitative assessment of extended-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997, 48(4): 817-21.
14. Hobart, J.C., Riazi, A., Lamping, D.L., Fitzpatrick, R., Thompson, A.J. Measuring the Impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology 2003, 60(1): 31-6. (Pubitemid 36070640)
15. Goodman, A.D., Schwid, S.R., Brown, T.R. et al. Sustained-release fampridine consistently improves walking speed and leg strength in multiple sclerosis: A phase 3 trial. Mult Scler 2008, 14(Suppl. 1): S298.
16. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198463.htm
17. Goodman, A.D., Brown, T.R., Edwards, K.R. et al. Interim analysis of open-label extension studies of dalfampridine extended release tablets in patients with multiple sclerosis. Neurology 2010, 74(Suppl. 2): A101.
18. Goodman, A.D., Brown, T.R., Edwards, K. et al. Characteristics of walking speed improvement observed in three well controlled studies of dalfampridine extended release tablets 10 mg bid in patients with multiple sclerosis. Neurology 2010, 74(Suppl. 2): A99.
19. Brown, T., Edwards, K., Goodman, A. et al., on behalf of the MS-F202, MS-F203, and MS-F204 Study Groups. Response to treatment with dalfampridine extended release tablets in patients with multiple sclerosis is independent of baseline. Neurology 2010, 74(Suppl. 2): A543.